Up-regulation of COX-2 and mPGES-1 by 27-hydroxycholesterol and 4-hydroxynonenal: A crucial role in atherosclerotic plaque instability

Free Radic Biol Med. 2018 Dec:129:354-363. doi: 10.1016/j.freeradbiomed.2018.09.046. Epub 2018 Oct 10.

Abstract

Atherosclerosis is currently understood to be mainly the consequence of a complicated inflammatory process at the different stages of plaque development. Among the several inflammatory molecules involved, up-regulation of the functional cyclooxygenase 2/membrane-bound prostaglandin E synthase 1 (COX-2/mPGES-1) axis plays a key role in plaque development. Excessive production of oxidized lipids, following low-density lipoprotein (LDL) oxidation, is a characteristic feature of atherosclerosis. Among the oxidized lipids of LDLs, the oxysterol 27-hydroxycholesterol (27-OH) and the aldehyde 4-hydroxynonenal (HNE) substantially accumulate in the atherosclerotic plaque, contributing to its progression and instability through a variety of processes. This study shows that 27-OH and HNE promote up-regulation of both the inducible enzymes COX-2 and mPGES-1, leading to increased production of prostaglandin (PG) E2 and inducible nitric oxide synthase, and the subsequent release of nitric oxide in human promonocytic U937 cells. The study also examined the potential involvement of the functionally coupled COX-2/mPGES-1 in enhancing the production of certain pro-inflammatory cytokines and of matrix metalloproteinase 9 by U937 cells. This enhancement is presumably due to the induction of PGE2 synthesis, as a result of the up-regulation of the COX-2/mPGES-1, stimulated by the two oxidized lipids, 27-OH and HNE. Induction of PGE2 synthesis might thus be a mechanism of plaque instability and eventual rupture, contributing to matrix metalloproteinase production by activated macrophages.

Keywords: 27-Hydroxycholesterol; 4-Hydroxynonenal; Atherosclerosis; Inflammation, Plaque instability.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Aldehydes / pharmacology*
  • Cell Line, Tumor
  • Cyclooxygenase 2 / genetics*
  • Cyclooxygenase 2 / metabolism
  • Dinoprostone / metabolism
  • Enzyme Activation / drug effects
  • Gene Expression Regulation
  • Humans
  • Hydroxycholesterols / pharmacology*
  • Lipoproteins, LDL / metabolism
  • Matrix Metalloproteinase 9 / genetics
  • Matrix Metalloproteinase 9 / metabolism
  • Models, Biological
  • Monocytes / drug effects*
  • Monocytes / metabolism
  • Monocytes / pathology
  • Nitric Oxide / metabolism
  • Nitric Oxide Synthase Type II / genetics
  • Nitric Oxide Synthase Type II / metabolism
  • Oxidation-Reduction
  • Plaque, Atherosclerotic / genetics
  • Plaque, Atherosclerotic / metabolism
  • Plaque, Atherosclerotic / pathology
  • Prostaglandin-E Synthases / genetics*
  • Prostaglandin-E Synthases / metabolism
  • Signal Transduction

Substances

  • Aldehydes
  • Hydroxycholesterols
  • Lipoproteins, LDL
  • Nitric Oxide
  • 27-hydroxycholesterol
  • NOS2 protein, human
  • Nitric Oxide Synthase Type II
  • Cyclooxygenase 2
  • MMP9 protein, human
  • Matrix Metalloproteinase 9
  • PTGES protein, human
  • Prostaglandin-E Synthases
  • 4-hydroxy-2-nonenal
  • Dinoprostone